Department of Laboratory Medicine & Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, South Korea.
Ann Hematol. 2013 Mar;92(3):357-64. doi: 10.1007/s00277-012-1628-6. Epub 2012 Nov 24.
Familial hemophagocytic lymphohistiocytosis (familial HLH or FHL) is a potentially fatal autosomal recessive disorder. Our previous study demonstrated that UNC13D mutations (FHL3) account for ~90 % of FHL in Korea with recurrent splicing mutation c.754-1G>C (IVS9-1G>C). Notably, half of the FHL3 patients had a monoallelic mutation of UNC13D. Deep intronic mutations in UNC13D were recently reported in patients of European descent. In this study, we performed targeted mutation analyses for deep intronic mutations and investigated on the founder effect in FHL3 in Korean patients. The study patients were 72 children with HLH including those with FHL3 previously reported to have a monoallelic UNC13D mutation. All patients were recruited from the Korean Registry of Hemophagocytic Lymphohistiocytosis. In addition to conventional sequencing of FHL2-4, targeted tests for c.118-308C>T and large intronic rearrangement mutations of UNC13D were performed. Haplotype analysis was performed for founder effects using polymorphic markers in the FHL3 locus. FHL mutations were detected in 20 patients (28 %). Seventeen patients had UNC13D mutations (FHL3, 85 %) and three had PRF1 mutations (FHL2, 15 %). UNC13D:c.118-308C>T was detected in ten patients, accounting for 38 % of all mutant alleles of UNC13D, followed by c.754-1G>C (26 %). Haplotype analyses revealed significantly shared haplotypes in both c.118-308C>T and c.754-1G>C, indicating the presence of founder effects. The deep intronic mutation UNC13D:c.118-308C>T accounts for the majority of previously missing mutations and is the most frequent mutation in FHL3 in Korea. Founder effects of two recurrent intronic mutations of UNC13D explain the unusual predominance of FHL3 in Korea.
家族性噬血细胞性淋巴组织细胞增生症(家族性 HLH 或 FHL)是一种潜在致命的常染色体隐性疾病。我们之前的研究表明,UNC13D 突变(FHL3)约占韩国 FHL 的 90%,且存在反复出现的剪接突变 c.754-1G>C(IVS9-1G>C)。值得注意的是,一半的 FHL3 患者 UNC13D 存在单等位基因突变。UNC13D 的深内含子突变最近在欧洲血统的患者中被报道。在这项研究中,我们对深内含子突变进行了靶向突变分析,并研究了韩国 FHL3 患者中的起源效应。研究患者为 72 名噬血细胞性淋巴组织细胞增生症患儿,包括先前报道存在 UNC13D 单等位基因突变的 FHL3 患儿。所有患者均来自韩国噬血细胞性淋巴组织细胞增生症登记处。除了对 FHL2-4 进行常规测序外,还对 UNC13D 的 c.118-308C>T 和大片段内含子重排突变进行了靶向检测。使用 FHL3 基因座中的多态性标记对起源效应进行单体型分析。在 20 名患者(28%)中检测到 FHL 突变。17 名患者存在 UNC13D 突变(FHL3,85%),3 名患者存在 PRF1 突变(FHL2,15%)。在 10 名患者中检测到 UNC13D:c.118-308C>T,占 UNC13D 所有突变等位基因的 38%,其次是 c.754-1G>C(26%)。单体型分析显示 c.118-308C>T 和 c.754-1G>C 存在显著共享单体型,表明存在起源效应。深内含子突变 UNC13D:c.118-308C>T 占先前缺失突变的大多数,是韩国 FHL3 中最常见的突变。UNC13D 两个反复出现的内含子突变的起源效应解释了 FHL3 在韩国异常流行的原因。